Novadaq Technologies Inc., a developer of real-time medical imaging systems and image guided therapies for the operating room, has announced the results of the first clinical experience utilizing the HELIOS Fluorescence Imaging System. The study, presented by Michel C. Samson, MD, interim Chairman, Department of Plastic Surgery at the Cleveland Clinic in Florida, during the World Congress for Reconstructive Micro Surgery held in Athens, Greece, June 24 - 26, confirmed that the use of intra-operative real-time laser- assisted fluorescent imaging during free-flap breast reconstructive surgery may result in improved intra-operative decision making for surgeons performing complex plastic surgery procedures and ultimately positively impact procedural outcomes for patients.
"Free tissue transfer is the most advanced and technically demanding form of reconstructive plastic surgery. This technique is utilized when reconstructing large defects created by trauma or neoplasm," said Dr. Michel C. Samson.
"Adequate blood-flow, both to and from transferred tissue, is the most critical component of this surgery. The ability to visually assess arterial inflow and venous return, on a real time basis, during these complex procedures assists us with intra-operative decision making and may ultimately prove to impact outcomes", according to study co-author Martin Newman, M.D., also of Cleveland Clinic in Florida.."
Novadaq also reported that results from a pilot study of the use of the LUNA Imaging System during surgery for kidney cancer were recently presented at the 2007 annual meeting of the American Urological Association by Dragan Golijanin, M.D, a urologist from the University of Rochester in Rochester, NY. The study included detailed analysis of images obtained utilizing the LUNA System during ten kidney cancer surgeries. Results showed that LUNA allowed surgeons to differentiate between healthy and malignant cancerous tissue which enabled more precise removal of the malignant tissue while preserving as much healthy tissue as possible. A critical factor in the future health of cancer patients.
"We have significant published data that demonstrates the clinical value of our lead product, the SPY System, during open heart cardiac surgery. Now surgeons from other specialties are finding significant value in using our technology during other complex operating room procedures," said Dr. Arun Menawat, President and CEO of Novadaq. "While SPY and the complementary surgical device for Trans Myocardial Revascularization (TMR) remain our short term revenue drivers, we are delighted to see that these new applications can significantly increase the potential opportunity for Novadaq.
